S-1: Aptevo Therapeutics Announces Public Offering of Common Stock and Warrants

Aptevo Therapeutics is launching a public offering to sell shares of common stock, pre-funded warrants, and common warrants to raise capital for working capital and general corporate purposes.

Summary

• Aptevo Therapeutics Inc. is undertaking a public offering of up to 922,509 shares of common stock along with common warrants to purchase up to 1,845,018 shares.
• The offering also includes pre-funded warrants for purchasers who would exceed ownership limits, exercisable for common stock at $0.0001 per share.
• Each share of common stock or pre-funded warrant is offered with two common warrants, exercisable at a price to be determined, expiring five years from issuance.
• The assumed combined public offering price is $5.42 per share and common warrant, based on the March 15, 2024, closing price.
• Roth Capital Partners, LLC is acting as the exclusive placement agent for the offering, which will end no later than three trading days from the prospectus date.
• The company intends to use the net proceeds of approximately $4.6 million for working capital and general corporate purposes, including the further development of its product candidates.
• The offering has no minimum number of shares or proceeds required to close, and investors may not receive a refund if the company does not sell all offered securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral. While the company is raising capital, which is generally positive, there are risks associated with the offering, such as dilution and the lack of a guaranteed minimum raise. The company's future outlook is positive, but it is still in the clinical stage and faces regulatory and development risks.

Positives

• The offering aims to provide Aptevo with additional working capital to advance its clinical programs.
• The inclusion of pre-funded warrants offers flexibility for investors with ownership limitations.
• The company retains discretion in allocating the net proceeds, allowing adaptation to evolving business conditions.

Negatives

• There is no guarantee that the company will sell all of the offered securities.
• The offering may result in immediate and substantial dilution for existing stockholders.
• There is no established public trading market for the common warrants or pre-funded warrants.
• The company has broad discretion in the use of the net proceeds from this offering and may not use them effectively.

Risks

• The company may not raise the amount of capital it believes is required for its business plans.
• Investors will experience immediate and substantial dilution in the net tangible book value per share.
• There is no public market for the common warrants or pre-funded warrants being offered.
• The common warrants and pre-funded warrants are speculative in nature.
• The placement agent has no obligation to buy any of the securities from the company or to arrange for the purchase or sale of any specific number or dollar amount of the securities.

Future Outlook

The company plans to advance its clinical candidates, continue preclinical development, and establish collaborative partnerships to broaden its pipeline and provide funding for research and development.

Industry Context

Bispecific therapeutics are increasingly recognized as potent anti-cancer agents, with nine new bispecific agents approved by the FDA in the last three years and a total of 125 bispecific drug candidates currently in development.

Comparison to Industry Standards

• The document mentions that nine new bispecific agents have been approved for use by the FDA in the last three years and there is a total of 125 bispecific drug candidates currently in development.
• The document states that Aptevo believes its candidates in development and its future molecules derived from its ADAPTIR and ADAPTIR-FLEX platforms will be highly competitive in the market as they are rationally designed for safety and tolerability as well as efficacy.

Stakeholder Impact

• Shareholders may experience dilution due to the issuance of new shares and warrants.
• Employees may benefit from the company's increased financial stability and ability to fund research and development.
• Customers (patients) may benefit from the development of new therapies.
• Suppliers and creditors may benefit from the company's improved financial position.

Next Steps

• Initiate a dose optimization Phase 1b/2 trial in the first half of 2024 for APVO436 in frontline AML patients.
• Continue investigating ALG.APV-527 for the treatment of multiple solid tumor types.
• Advance APVO603 and APVO442 through preclinical and IND-enabling studies.
• Further evaluate the mechanism of action and efficacy of APVO711 through preclinical studies.

Key Dates

Keywords

common stock, warrants, public offering, Aptevo Therapeutics, pre-funded warrants, Roth Capital Partners, capital raise, securities, placement agent, dilution